Clinical study of the relationship between Copeptin and new-onset atrial fibrillation in patients with acute myocardial infarction
Abstract：Objective To explore the correlation between C-terminal portion of provasopressin(Copeptin) and new-onset atrial fibrillation in patients with acute myocardial infarction (AMI). Methods We selected 228 subjects with acute myocardial infarction (AMI). All patients were monitored continuously for new-onset atrial fib-rillation (AF)for 7 days since admission. All patients were divided into a group with new-onset AF and a group without new-onset AF. Admission plasma Copeptin was measured by enzyme-linked immunosorbent assay(ELISA). Results The admission plasma levels of Copeptin in new-onset AF group were higher than the without new -onset AF (21.2 pmol/L vs 9.6 pmol/L,P<0.05). Multivariate logistic regression analysis revealed that admission heart rate(OR=1.059,95%CI 0.999-1.123,P=0.042),Copeptin levels(OR=4.685,95%CI 1.729-12.692,P=0.002), left atrial diameter(LAD)(OR=1.204,95%CI 1.069-1.355,P=0.002)were significantly and independently associ-ated with new-onset AF in patients with AMI. Conclusion Copeptin levels are effective predictor of new-onset AF in patients with AMI.
Keywords：Acute myocardial infarctionAtrial fibrillationCopeptin
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 249-252 )